- Home
- ATOS vs SSSS Comparison
ATOS vs SSSS Comparison
Compare ATOS & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- SSSS
- Stock Information
- Founded
- ATOS 2009
- SSSS 2010
- Country
- ATOS United States
- SSSS United States
- Employees
- ATOS N/A
- SSSS N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- SSSS Finance: Consumer Services
- Sector
- ATOS Health Care
- SSSS Finance
- Exchange
- ATOS Nasdaq
- SSSS Nasdaq
- Market Cap
- ATOS 114.5M
- SSSS 134.1M
- IPO Year
- ATOS 2012
- SSSS N/A
- Fundamental
- Price
- ATOS $0.80
- SSSS $5.92
- Analyst Decision
- ATOS Strong Buy
- SSSS Buy
- Analyst Count
- ATOS 3
- SSSS 2
- Target Price
- ATOS $7.00
- SSSS $7.00
- AVG Volume (30 Days)
- ATOS 678.1K
- SSSS 334.9K
- Earning Date
- ATOS 03-31-2025
- SSSS 03-12-2025
- Dividend Yield
- ATOS N/A
- SSSS N/A
- EPS Growth
- ATOS N/A
- SSSS N/A
- EPS
- ATOS N/A
- SSSS N/A
- Revenue
- ATOS N/A
- SSSS $5,903,895.00
- Revenue This Year
- ATOS N/A
- SSSS N/A
- Revenue Next Year
- ATOS N/A
- SSSS N/A
- P/E Ratio
- ATOS N/A
- SSSS N/A
- Revenue Growth
- ATOS N/A
- SSSS 5.43
- 52 Week Low
- ATOS $0.72
- SSSS $3.52
- 52 Week High
- ATOS $2.31
- SSSS $6.83
- Technical
- Relative Strength Index (RSI)
- ATOS 41.00
- SSSS 49.18
- Support Level
- ATOS $0.79
- SSSS $6.08
- Resistance Level
- ATOS $0.89
- SSSS $6.67
- Average True Range (ATR)
- ATOS 0.05
- SSSS 0.44
- MACD
- ATOS 0.01
- SSSS 0.05
- Stochastic Oscillator
- ATOS 25.14
- SSSS 50.27
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.